In another trial evaluating atezolizumab in m-ccRCC patients, a biomarkers study showed that plasma VEGF-A decreased in responders but was stable in patients with stable disease or progressive disease [80]. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.